文献速递泌尿系结石

比较Bard Inlay Optima与Cook Universa Soft支架的前瞻性随机对照多中心试验

A Prospective, Randomized Controlled Multicenter Trial Comparing the Bard Inlay Optima and the Cook Universa Soft Stent.
PubMed 文献 · Urology · 2023-08-10

这项前瞻性双盲随机对照多中心试验将140例因泌尿系结石或肾盂输尿管连接部梗阻置入单侧逆行双J支架的患者按1:1随机分入Bard Inlay Optima组与Cook Universa Soft组,用输尿管支架症状问卷(USSQ)评估。两组在所有USSQ领域指数评分、早期拔管及术后阿片类药物使用上均无显著差异;Cook Universa Soft组第1周自报尿路感染症状评分更高(3.1±1.3 vs 2.6±1.3,P=.05),第1周和第3周再就诊率更高,但按招募中心校正后不再显著。结论认为Bard Inlay Optima的pHreecoat抗炎涂层未带来术后总体症状的显著差异。

要点

  • 两组在所有USSQ领域指数评分、早期拔管及术后阿片类药物使用上均无显著差异。
  • Cook Universa Soft组第1周自报尿路感染症状评分高于Bard Inlay Optima组(3.1±1.3 vs 2.6±1.3,P=.05)。
  • Cook Universa Soft组再就诊率第1周为16%(10例)vs 2%(1例),第3周为25%(15例)vs 5%(3例),按招募中心校正后不再显著(第1周P=.27;第3周P=.22)。

核心结论

  • Bard Inlay Optima的pHreecoat抗炎涂层未能在泌尿、疼痛、总体和性健康领域带来术后总体症状的显著差异。

研究设计与样本

  • 前瞻性、双盲、随机对照多中心试验,在三个公立泌尿外科服务点开展。
  • 140例因泌尿系结石或肾盂输尿管连接部梗阻接受单侧逆行双J支架置入且符合纳入标准的患者,按1:1随机分入两种支架。
  • 主要终点为第1周和第3周USSQ泌尿、疼痛、总体和性健康领域的平均指数评分。

主要发现

  • 两种支架在所有USSQ领域指数评分、早期拔管或术后阿片类药物使用方面均无显著差异。
  • Cook Universa Soft组第1周自报尿路感染症状评分高于Bard Inlay Optima组(3.1±1.3 vs 2.6±1.3,P=.05)。
  • Cook Universa Soft组再就诊率第1周为16%(10例)vs 2%(1例),P<.001;第3周为25%(15例)vs 5%(3例),P<.001。
  • 按招募中心校正后,再就诊率差异不再显著(第1周P=.27;第3周P=.22)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine if the Bard Inlay Optima with its anti-inflammatory pHreecoat stent coating had reduced stent-related symptoms at Week 1 (W1) and Week 3 (W3) post insertion compared to the Cook Universa Soft (CUS) using the validated Ureteral Stent Symptoms Questionnaire (USSQ). METHODS: A prospective, double-blinded, randomized controlled trial was performed on patients receiving unilateral retrograde double-J stents for urolithiasis or pelviureteric junction obstruction at three public Urology services. One hundred forty patients that met inclusion criteria were randomized in a 1:1 ratio to each stent. Primary endpoints were the mean USSQ index scores for the urinary, pain, general, and sexual health domains at W1 and W3. Secondary endpoints were responses to individual USSQ questions, early stent removal, and postoperative opioid use. RESULTS: No significant difference was found between the two stents in terms of index scores for all USSQ domains, early stent removal or postoperative opioid use. The CUS had worse symptom scores at W1 relating to self-reported urinary tract infection symptoms (3.1 ± 1.3 vs 2.6 ± 1.3, P = .05). The CUS was also associated with higher rate of representation to hospital at W1 (n = 10, 16% vs n = 1, 2%, P < .001) and W3 (n = 15, 25% vs n = 3, 5%, P < .001). This did not remain significant when adjusted to site of recruitment (W1 P = .27; W3 P = .22). CONCLUSION: The Bard Inlay Optima's anti-inflammatory pHreecoat stent coating did not translate to any significant difference in overall postoperative symptoms across urinary, pain, general, and sexual health domains.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Ngoo A, Kwok M, Ong M, et al. A Prospective, Randomized Controlled Multicenter Trial Comparing the Bard Inlay Optima and the Cook Universa Soft Stent. Urology. 2023. PMID: 37572885. doi:10.1016/j.urology.2023.07.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。